We are international
Donate
• myeloma tv TEXT SIZE   

ASH 2011

The 53rd Annual Meeting of the American Society of Hematology (ASH) took place in San Diego, California December 10-13, 2011. The webcasts taped at the meeting are reports on the current status of some of the most interesting research in myeloma. Please be aware that at the time of posting, in some cases, the interviewees are reporting on interim data from incomplete clinical trials. Therefore not all the data presented are final results, and it is possible that results will be different when the data has matured with long-term follow-up. None of this research has yet been peer-reviewed and published in a medical journal.

Bortezomib
ASH 2011: Dr. Richardson - Phase II Study of the Pan-Deacetylase Inhibitor Panobinostat in Combination with Bortezomib and Dexamethasone in Relapsed and Bortezomib-Refractory Multiple Myeloma (PANORAMA 2)
Paul G. Richardson, MD
Dana-Farber Cancer Institute
Boston, Massachusetts, USA
ASH 2011: Dr. San Miguel - Continued Overall Survival Benefit After 5 Years’ Follow-up with Bortezomib-Melphalan-Prednisone (VMP) Versus Melphalan-Prednisone (MP) in Patients with Previously Untreated Multiple Myeloma, and No Increased Risk of Second Primary Malignancies: Final Results of the Phase 3 VISTA Trial
Jesús F San Miguel, MD PhD
Hospital Clinico Universitario
Salamanca, Spain

ASH 2011: Dr. Niesvizky - Preliminary Results of a Phase I/II Study of PD 0332991 in Combination with Bortezomib and Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma
Ruben Niesvizky, MD
Weill Cornell Medical College
New York, New York, USA
ASH 2011: Dr. Nooka - The Improved Efficacy of Bortezomib Containing Induction Regimens (BCIR) Versus Non-Bortezomib Containing Induction Regimens (NBCIR) in Transplant-Eligible Patients with Multiple Myeloma (MM): Meta-Analysis of Phase III Randomized Controlled Trials (RCTs)
Ajay Nooka, MD, MPH, FACP
Winship Cancer Institute of Emory University
Atlanta, Georgia, USA

ASH 2011: Dr. Siegel - Vantage 095: Vorinostat in Combination with Bortezomib in Salvage Multiple Myeloma Patients: Final Study Results of a Global Phase 2b Trial
David S. Siegel, MD, PhD
Hackensack University Medical Center
Hackensack, New Jersey, USA
ASH 2011: Dr. Mateos - Maintenance Therapy with Bortezomib Plus Thalidomide (VT) or Bortezomib Plus Prednisone (VP) In Elderly Myeloma Patients Included In the GEM2005MAS65 Spanish Randomized Trial
María-Victoria Mateos, MD, PhD
Hospital Clinico Universitario
Salamanca, Spain

ASH 2011: Dr. Munshi - Once a Week Bortezomib with Dexamethasone Is Effective with Limited Toxicity in Newly Diagnosed Multiple Myeloma Patients with Older Age and Co-Morbidities
Nikhil C. Munshi, MD
Dana-Farber Cancer Institute
Boston, Massachusetts, USA
ASH 2011: Dr. Niesvizky - Efficacy and Safety of Three Bortezomib-Based Combinations in Elderly, Newly Diagnosed Multiple Myeloma Patients: Results From All Randomized Patients in the Community-Based, Phase 3b UPFRONT Study
Ruben Niesvizky, MD
Weill Cornell Medical College
New York, New York, USA

ASH 2011: Dr. Ludwig - Bortezomib-Bendamustine-Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (MM) Shows Marked Efficacy and Is Well Tolerated, but Assessment of PNP Symptoms Shows Significant Discrepancies Between Patients and Physicians
Heinz Ludwig, MD
Wilhelminenhospital
Vienna, Austria